SPARCL1 Suppresses Metastasis in Prostate Cancer

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2013 Aug 7

PMID 23916135

Citations 27

Authors

Yuzhu Xiang

Qingchao Qiu

Ming Jiang

Renjie Jin

Brian D Lehmann

Douglas W Strand

Bojana Jovanovic

David J DeGraff

Yi Zheng

Dina A Yousif

Christine Q Simmons

Thomas C Case

Jia Yi

Justin M Cates

John Virostko

Xiusheng He

Xunbo Jin

Simon W Hayward

Robert J Matusik

Alfred L George Jr

Yajun Yi

Affiliations

Soon will be listed here.

Abstract

Purpose: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level.

Experimental Design: Based on a pattern of reduced expression in human prostate cancer tissues and tumor cell lines, a candidate suppressor gene (SPARCL1) was identified. We used in vitro approaches to determine whether overexpression of SPARCL1 affects cell growth, migration, and invasiveness. We then employed xenograft mouse models to analyze the impact of SPARCL1 on prostate cancer cell growth and metastasis in vivo.

Results: SPARCL1 expression did not inhibit tumor cell proliferation in vitro. By contrast, SPARCL1 did suppress tumor cell migration and invasiveness in vitro and tumor metastatic growth in vivo, conferring improved survival in xenograft mouse models.

Conclusions: We present the first in vivo data suggesting that SPARCL1 suppresses metastasis of prostate cancer.

Citing Articles

The oncogenic functions of SPARCL1 in bladder cancer.

Li C, Yuan H, Chen J, Shang K, He H J Cell Mol Med. 2024; 28(22):e70196.

PMID: 39548034 PMC: 11567778. DOI: 10.1111/jcmm.70196.

Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.

Pavlovic B, Brautigam K, Dartiguenave F, Martel P, Rakauskas A, Cesson V Sci Rep. 2024; 14(1):18148.

PMID: 39103428 PMC: 11300834. DOI: 10.1038/s41598-024-68026-1.

SPARCL1 promotes chondrocytes extracellular matrix degradation and inflammation in osteoarthritis via TNF/NF-κB pathway.

Miao Y, Wu S, Gong Z, Chen Y, Xue F, Liu K J Orthop Translat. 2024; 46:116-128.

PMID: 38867741 PMC: 11167206. DOI: 10.1016/j.jot.2024.02.009.

Integrating the characteristic genes of macrophage pseudotime analysis in single-cell RNA-seq to construct a prediction model of atherosclerosis.

Tian Z, Yang S Aging (Albany NY). 2023; 15(13):6361-6379.

PMID: 37421595 PMC: 10373969. DOI: 10.18632/aging.204856.

Identifying liver metastasis-related hub genes in breast cancer and characterizing as a potential prognostic biomarker.

Chen M, Zheng W, Fang L PeerJ. 2023; 11:e15311.

PMID: 37180578 PMC: 10174054. DOI: 10.7717/peerj.15311.

References

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V . ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One. 2010; 5(5):e10547. PMC: 2866657. DOI: 10.1371/journal.pone.0010547. View

Chandran U, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W . Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007; 7:64. PMC: 1865555. DOI: 10.1186/1471-2407-7-64. View

Vander Griend D, Rinker-Schaeffer C . A new look at an old problem: the survival and organ-specific growth of metastases. Sci STKE. 2004; 2004(216):pe3. DOI: 10.1126/stke.2162004pe3. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Park S, Kim S, McCauley L, Gallick G . Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol. 2011; Chapter 14:Unit 14.15. PMC: 3072580. DOI: 10.1002/0471141755.ph1415s51. View

Hurley P, Marchionni L, Simons B, Ross A, Peskoe S, Miller R . Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012; 109(37):14977-82. PMC: 3443123. DOI: 10.1073/pnas.1203525109. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P . Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res. 2012; 18(19):5438-48. DOI: 10.1158/1078-0432.CCR-12-0124. View

Price P, McMILLAN T . Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res. 1990; 50(5):1392-6. View

10.

Hambrock H, Nitsche D, Hansen U, Bruckner P, Paulsson M, Maurer P . SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem. 2003; 278(13):11351-8. DOI: 10.1074/jbc.M212291200. View

11.

Girard J, Springer T . Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 1995; 2(1):113-23. DOI: 10.1016/1074-7613(95)90083-7. View

12.

Seraj M, Samant R, Verderame M, Welch D . Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 2000; 60(11):2764-9. View

13.

Lloyd-Burton S, Roskams A . SPARC-like 1 (SC1) is a diversely expressed and developmentally regulated matricellular protein that does not compensate for the absence of SPARC in the CNS. J Comp Neurol. 2011; 520(12):2575-90. DOI: 10.1002/cne.23029. View

14.

Girard J, Springer T . Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem. 1996; 271(8):4511-7. DOI: 10.1074/jbc.271.8.4511. View

15.

Xu J, Wang R, Xie Z, Odero-Marah V, Pathak S, Multani A . Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 2006; 66(15):1664-73. DOI: 10.1002/pros.20488. View

16.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

17.

Yi Y, Li C, Miller C, George Jr A . Strategy for encoding and comparison of gene expression signatures. Genome Biol. 2007; 8(7):R133. PMC: 2323223. DOI: 10.1186/gb-2007-8-7-r133. View

18.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

19.

Steeg P . Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003; 3(1):55-63. DOI: 10.1038/nrc967. View

20.

Ramos D, Chen B, Regezi J, Zardi L, Pytela R . Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer. 1998; 75(5):680-7. DOI: 10.1002/(sici)1097-0215(19980302)75:5<680::aid-ijc4>3.0.co;2-v. View